FDA Developing Initiatives to Improve Quality of Drug Master Files
This article was originally published in The Gold Sheet
Executive Summary
The quality of DMFs is expected to improve thanks to a soon to be released question- based review system for DMF holders as well a recently issued draft guidance calling for new procedures for reviewing master files called “completeness assessments,” said a pharmaceutical industry official who was a former team leader in FDA’s Office of Generic Drugs.
You may also be interested in...
FDA Clarifies Expectations for Completeness Assessments for Drug Master Files
FDA has clarified its requirements for DMF completeness acceptance following complaints that the draft guidance was too vague. FDA elaborates on what constitutes a single drug substance, single manufacturing process and starting materials.
FDA Says DMF Filings Held Up by Inadequate Information on Starting Materials
FDA officials say that only 14 percent of Type II drug master file completeness assessments are being approved in the first review cycle and urged industry to meet with them via the 10-day teleconference to resolve issues early on. Inadequate information on starting materials is a major deficiency and one of the most intractable problems found in API DMF filings, they say.
FDA Proposes QbR for New Drugs to Level the Playing Field for CMC Reviews
FDA has proposed to expand the use of question-based review, or QbR, to new drugs as part of its efforts to harmonize new and generic drug chemistry reviews. This reflects the agency’s latest efforts to improve the quality of brand and generic drugs by levying “equal expectations” for both.